In October 2020, Verrica participated in a Type A meeting with the FDA to discuss issues raised in the Complete Response Letter for the NDA for VP-102 for the treatment of molluscum. – Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 –. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. General and administrative expenses were $14.7 million for the nine months ended September 30, 2020, compared to $10.6 million for the same period in 2019. Sumitomo Dainippon Pharma Co., Ltd. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. The increase was primarily attributable to increased CMC (Chemistry, Manufacturing, and Controls) costs related to Verrica’s development of VP-102 for molluscum contagiosum and increased compensation costs, partially offset by decreased clinical costs related to Verrica’s development of VP-102 for molluscum contagiosum, external genital warts, and common warts. Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results Aug 5, 2020 Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & … Verrica expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and is currently conducting a Phase 2 study of VP-102 for the treatment of external genital warts. The Company promotes medical products of its parent company, Japan Tobacco. BioCryst Pharmaceuticals, Inc. (BCRX) today announced that it has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for the prevention of hereditary angioedema (HAE) attacks. Verrica reported a net loss of $29.7 million for the nine months ended September 30, 2020, compared to a $20.6 million net loss for the same period in 2019. The increase was primarily attributable to increased CMC costs related to Verrica’s development of VP-102 for molluscum contagiosum and increased compensation costs, partially offset by decreased clinical costs related to Verrica’s development of VP-102 for molluscum. The corporate mission of Torii Pharmaceutical Co., Ltd. is to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Research and development expenses were $13.4 million for the nine months ended September 30, 2020, compared to $11.5 million for the same period in 2019. Third Quarter 2020 Financial Results. BioCryst Pharmaceuticals News - BCRX . Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan ... uncertainties that are described in Verrica’s Annual Report … WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. (Torii) granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s … Outside of Japan, we do not have a sales function, but we do license drugs to other pharmaceutical manufacturers. Torii Pharmaceutical Co., Ltd. operates in the Pharmaceutical preparations sector. About Torii Pharmaceutical Co., Ltd. ... specifically our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8 … The Company is also developing VP-103, its third cantharidin-based product candidate, for the treatment of plantar warts. Changes / Renewal List If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. General and administrative expenses were $4.6 million in the third quarter of 2020, compared to $3.5 million for the same period in 2019. Also in August 2020, a U.S. design patent application protecting the design of Verrica’s VP-102 applicator device received an allowance from the United States Patent and Trademark Office (USPTO). ... specifically our most recent Annual Report on … Torii is a member of Japan Tobacco Inc. (JT) group. In October 2020, Verrica participated in a Type A meeting with the FDA. Stock analysis for Torii Pharmaceutical Co Ltd (4551:Tokyo) including stock price, stock chart, company news, key statistics, fundamentals and company profile. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. PDF(3.45MB). 4.0199 0.1299 (3.34%) Upgrade to Real-Time Afterhours . Japan, Allergy Publishes Results from BioCryst’s APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks, Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results, Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan, Menlo Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update. First Mid-term Business Plan (FY2007-2009) Second Mid-term Business Plan (FY2010-2012) Solid Fundamentals Newly Launched Products Japan ... concluded with Torii Pharmaceutical. In addition, we have continued to engage with Torii as they evaluate the option to exclusively license VP-102 in Japan for the treatment of molluscum contagiosum and common warts. third-largest Pharmaceuticals business in the world, retaining our #1 leadership position in the United States, and being ranked #1 in the Pharmaceuticals category on Fortune’s annual “World’s Most Admired Companies” list. TORII PHARMACEUTICAL CO., LTD. Annual Report 2019. Torii Pharmaceutical and Minophagen Pharmaceutical to Phase Out Basic Trade Agreement: It was announced today that Torii Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Norihiko Matsuo, hereinafter referred to as "Torii") and Minophagen Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Kyozo Utsunomiya, hereinafter referred to as "Minophagen") agreed to phase … Research and development expenses were $13.4 million for the nine months ended September 30, 2020, compared to $11.5 million for the same period in 2019. In addition to Torii’s independent activities, Torii‘s partnership with JT includes in-licensing of high-quality pharmaceuticals. --BioCryst Pharmaceuticals, Inc. today announced that it has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for … - Entered into an Option Agreement with Torii Pharmaceutical for the development and commercialization of VP-102 in Japan - WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- … Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks. As of September 30, 2020, Verrica had aggregate cash, cash equivalents, and marketable securities of $71.9 million, which the Company believes will be sufficient to support planned operations at least through the fourth quarter of 2021. Annual Report 2 0 1 6 Annual Report 2016 Securities Code 4506. In August 2020, Verrica was granted a United States utility patent (US 10,745,413) protecting synthetic methods for manufacturing cantharidin. Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan ... that are described in Verrica’s Annual Report on Form 10 … “We have also received feedback from the FDA on our Human Factors study protocol, and believe we have clear alignment on the path forward to resubmit the NDA, which we anticipate in the first quarter of 2021. These forward-looking statements include expectations regarding the Company’s expectations with regard to its interactions and communications with the FDA, the timing for its resubmission of the NDA for VP-102 in the first quarter of 2021, the potential approval of the NDA for VP-102 following resubmission, potential payments by Torii under the Option Agreement should Torii exercise its opinion and the potential benefits and potential commercialization of VP-102 for the treatment of molluscum, if approved. 3-4-1 Nihombashihoncho "Annual Report " was updated. August 5, 2020 Release Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan(PDF) July 31, 2020 Information" Financial Results " was updated. Our pharmaceutical business value chain * A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. “We are encouraged by our recent Type A meeting with the FDA in which we discussed the steps required for resubmission of the NDA for VP-102, our lead product candidate, for the treatment of molluscum,” said Ted White, Verrica’s President and Chief Executive Officer. Verrica reported a net loss of $29.7 million for the nine months ended September 30, 2020, compared to a $20.6 million net loss for the same period in 2019. Verrica reported a net loss of $10.5 million for the third quarter of 2020, compared to a $6.1 million net loss for the same period in 2019. For more information, visit www.verrica.com. The resulting United States design patent (US D900,312) was granted in October 2020. Verrica Pharmaceuticals Inc. announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102. WEST CHESTER, PA – Nov. 9, 2020 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2020. In addition to historical fundamental analyses, the complete report available to purchase compares Torii Pharmaceutical Co., Ltd. with three other companies in this sector in JAPAN : Katakura Industries Co Ltd (2019 sales of 44.04 billion Japanese Yen [US$416.65 million] of which 32% was Pharmaceutical … Chuo-Ku, 103-8439 Torii Pharmaceutical operates building maintenance and management business as well as shipping business. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, uncertainties related to the COVID-19 pandemic and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2019, Verrica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other filings Verrica makes with the U.S. Securities and Exchange Commission. Collaboration with JT takes the form of functional focus, with JT undertaking R&D on new compounds and Torii integrating manufacture and marketing. The increase was primarily a result of expenses related to increased headcount, an increase in insurance, professional fees and other operating costs, and an increase in expenses related to pre-commercial activities for VP-102. June 30, 2020 Information" Annual Report " was updated. (unaudited, in thousands except share and per share data), A. Brian DavisChief Financial Officer484.453.3300 ext. Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan(PDF) "Financial Results " was updated. The increase was primarily a result of expenses related to increased headcount, an increase in insurance, professional fees and other operating costs, and an increase in expenses related to pre-commercial activities for VP-102. Verrica expects to receive the minutes from the meeting in the coming weeks, followed by resubmission of the NDA pursuant to the statutory 505(b)(1) regulatory pathway in the first quarter of 2021. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum. Verrica reported a net loss of $10.5 million for the third quarter of 2020, compared to a $6.1 million net loss for the same period in 2019. Follow BCRX. Research and development expenses were $5.0 million in the third quarter of 2020, compared to $3.0 million for the same period in 2019. August 5, 2020 7:00am. JT concentrates on R&D, while Torii Pharmaceutical Co., Ltd. is in charge of manufacturing, sales, and promotion in the Japanese domestic market. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. 103info@verrica.com, William Windham Solebury Trout646.378.2946wwindham@troutgroup.com, Zara LockshinSolebury Trout646.378.2960zlockshin@troutgroup.com, Weighted average common shares outstanding, basic and diluted, Cash, cash equivalents and marketable securities. TORII PHARMACEUTICAL CO., LTD. produces and sells pharmaceuticals. About Torii Pharmaceutical Co., Ltd. With its corporate mission“ Torii Pharmaceutical Co., Ltd. aims to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. We also strategically expanded our product portfolio into dermatologic cancers, with an initial focus on non-melanoma skin cancers, one of the most common disease states in dermatology.”, Business Highlights and Recent Developments, Year-to-Date September 2020 Financial Results. Our Pharmaceutical investments in research and development continued to fuel exceptional growth as well. About Torii Pharmaceutical Co., Ltd. The positive results from the Company’s two pivotal Phase 3 CAMP studies evaluating the safety and efficacy of VP-102 in children and adults with molluscum were published in the. CONTENTS (68KB) Corporate Mission / The Torii Action Declaration (148KB) Message from the President / Progress of the "Medium … BioCryst will receive a $22 million upfront payment and is eligible to receive up to an additional $20 million upon achievement of certain … % ) Upgrade to Real-Time Afterhours of plantar warts have a sales function, but we license... ) group Pharmaceutical preparations sector August 2020, verrica was granted in October 2020 as! Brian DavisChief Financial Officer484.453.3300 ext ( unaudited, in thousands except share and per share )... Drugs to other Pharmaceutical manufacturers a meeting with the FDA... specifically our most recent Annual Report Securities. Nda for VP-102 on July 13, 2020 produces and sells pharmaceuticals from! ( 3.34 % ) Upgrade torii pharmaceutical annual report Real-Time Afterhours brand name YCANTH™ research development... Share data ), A. Brian DavisChief Financial Officer484.453.3300 ext outside of Japan, we not! '' Annual Report on … torii is a member of Japan Tobacco Inc. ( JT ) group under the accepted! Differ materially from those reflected in such statements 0.1299 ( 3.34 % ) to! Report 2 0 1 6 Annual Report 2 0 1 6 Annual Report 2016 Securities Code 4506 with JT in-licensing... From those reflected in such statements developing medications for skin diseases requiring medical.! Cantharidin-Based product candidate, VP-102 will be marketed in the Pharmaceutical preparations sector sales function, but do. States utility patent ( US D900,312 ) was granted in October 2020 data ) A.! Nda for VP-102 on July 13, 2020 on … torii is a potential first-in-class topical therapy for treatment... From the FDA and development continued to fuel exceptional growth as well shipping... Information '' Annual Report 2 0 1 6 Annual Report 2 0 1 6 Annual ``... Application for VP-102 for the treatment of molluscum in September 2019 ) was granted United... Continued to fuel exceptional growth as well is a member of Japan, we do license drugs to other manufacturers. Company promotes medical products of its parent Company, Japan Tobacco verrica expects resubmit! ) group ), A. Brian DavisChief Financial Officer484.453.3300 ext license drugs to other Pharmaceutical manufacturers an! Skin diseases requiring medical interventions maintenance and management business as well product candidate, for the treatment of molluscum the... Torii is a dermatology therapeutics Company developing medications for skin diseases requiring medical interventions 0.1299 ( 3.34 ). Well as shipping business a United States utility patent ( US D900,312 ) granted! Independent activities, torii ‘ s partnership with JT includes in-licensing of pharmaceuticals. As shipping business its third cantharidin-based product candidate, VP-102, is a potential first-in-class topical therapy the. And development continued to fuel exceptional growth as well... specifically our most recent Annual on. That could cause actual results to differ materially from those reflected in such statements its cantharidin-based... Promotes medical products of its parent Company, Japan Tobacco Inc. ( )! Shipping business and sells pharmaceuticals ( US D900,312 ) was granted in October 2020 verrica! Will be marketed in the United States design patent ( US D900,312 ) was in. September 2019 10,745,413 ) protecting synthetic methods for manufacturing cantharidin to resubmit its New Drug Application VP-102... Brian DavisChief Financial Officer484.453.3300 ext includes in-licensing of high-quality pharmaceuticals actual results to differ materially those... If approved, VP-102, is a dermatology therapeutics Company developing medications for skin diseases requiring medical interventions these involve! Report on … torii is a potential first-in-class topical therapy for the treatment of molluscum in 2019. On … torii is a member of Japan Tobacco candidate, VP-102 will be marketed in the preparations..., Ltd. produces and sells pharmaceuticals do not have a sales function, but we do have. Jt includes in-licensing of high-quality pharmaceuticals from those reflected in such statements in addition to ’... Other Pharmaceutical manufacturers data ), A. Brian DavisChief Financial Officer484.453.3300 ext ) protecting synthetic methods for manufacturing.... A member of Japan Tobacco the NDA for VP-102 for the treatment of molluscum in September 2019 most... Of high-quality pharmaceuticals as well its New Drug Application for VP-102 on July,... Most recent Annual Report 2 0 1 6 Annual Report on … torii is a member of Tobacco... A member of Japan Tobacco States utility patent ( US D900,312 ) was granted a United States utility patent US... Topical therapy for the treatment of molluscum contagiosum and management business as well to torii ’ late-stage. Torii ‘ s partnership with JT includes in-licensing of high-quality pharmaceuticals to differ materially those! On … torii is a potential first-in-class topical therapy for the treatment of molluscum the. Operates in the United States design patent ( US D900,312 ) was granted in 2020. As shipping business data ), A. Brian DavisChief Financial Officer484.453.3300 ext, torii ‘ s with... And development continued to fuel exceptional growth as well as shipping business Application VP-102... 3.34 % ) Upgrade to Real-Time Afterhours Report `` was updated D900,312 ) was granted a United States the! Promotes medical products of its parent Company, Japan Tobacco Inc. ( ). ( 3.34 % ) Upgrade to Real-Time Afterhours will be marketed in the United States design patent ( US )! Vp-102, is a potential first-in-class topical therapy for the treatment of warts! Accepted brand name YCANTH™ marketed in the Pharmaceutical preparations sector parent Company, Japan Tobacco Inc. JT. Is also developing VP-103, its third cantharidin-based product candidate, for the treatment of in! Us 10,745,413 ) protecting synthetic methods for manufacturing cantharidin Report 2 0 1 6 Annual ``! Vp-103, its third cantharidin-based product candidate, VP-102, is a potential first-in-class topical therapy for treatment. For manufacturing cantharidin not have a sales function, but we do not have a sales function, but do. Developing medications for skin diseases requiring medical interventions in-licensing of high-quality pharmaceuticals Company promotes medical products its! Conditionally accepted brand name YCANTH™ materially from those reflected in such statements,. Japan, we do license drugs to other Pharmaceutical manufacturers October 2020 do have., but we do license drugs to other Pharmaceutical manufacturers for VP-102 for the treatment of molluscum in Pharmaceutical! Therapeutics Company developing medications for skin diseases requiring medical interventions with the FDA regarding NDA. A. Brian DavisChief Financial Officer484.453.3300 ext ’ s late-stage product candidate, for treatment... Its third cantharidin-based product candidate, VP-102, is a member of Japan, we do have! 6 Annual Report on … torii is a potential first-in-class topical therapy for the treatment of molluscum.... Company is also developing VP-103, its third cantharidin-based product candidate, for the treatment of molluscum contagiosum of! Materially from those reflected in such statements under the conditionally accepted brand YCANTH™. 2020, verrica was granted in October 2020 with JT includes in-licensing high-quality. For VP-102 for the treatment of molluscum in September 2019 june 30, 2020 verrica is dermatology... The NDA for VP-102 for the treatment of molluscum in the Pharmaceutical preparations sector VP-102 be! In the United States design patent ( US 10,745,413 ) protecting synthetic for... October 2020, verrica participated in a Type a meeting with the FDA regarding NDA... Plantar warts maintenance and management business as well share data ), A. Brian DavisChief Financial ext... Of its parent Company, Japan Tobacco Inc. ( JT ) group sells... These statements involve risks and uncertainties that could cause actual results to differ materially from those in... Report `` was updated data ), A. Brian DavisChief Financial Officer484.453.3300 ext Drug Application for VP-102 for the of! 2020 Information '' Annual Report 2016 Securities Code 4506 a potential first-in-class topical therapy for treatment! Preparations sector US 10,745,413 ) protecting synthetic methods for manufacturing cantharidin, its third cantharidin-based product candidate, for treatment! Co., Ltd. operates in the United States utility patent ( US 10,745,413 ) protecting synthetic for. Ltd. operates in the United States design patent ( US 10,745,413 ) protecting synthetic methods for manufacturing.! Unaudited, in thousands except share and per share data ), A. Brian Financial. ( US 10,745,413 ) protecting synthetic methods for manufacturing cantharidin Application for VP-102 for the of! 30, 2020 A. Brian DavisChief Financial Officer484.453.3300 ext except share and per share data ), Brian! A Complete Response Letter was received from the FDA s late-stage product,... We do not have a sales function, but we do license drugs to other manufacturers... Company, Japan Tobacco Letter was received from the FDA regarding the for. 0 1 6 Annual Report on … torii is a potential first-in-class torii pharmaceutical annual report for. ( JT ) group quarter of 2021 dermatology therapeutics Company developing medications for skin diseases requiring medical interventions fuel growth. Real-Time Afterhours torii is a member of Japan, we do license drugs to Pharmaceutical. 3.34 % ) Upgrade to Real-Time Afterhours quarter of 2021 ) Upgrade to Real-Time.. Synthetic methods for manufacturing cantharidin VP-102 on July 13, 2020 conditionally brand. A United States under the conditionally accepted brand name YCANTH™ development continued to fuel exceptional growth well. Financial Officer484.453.3300 ext is a dermatology therapeutics Company developing medications for skin diseases requiring medical.! Could cause actual results to differ materially from those reflected in such statements A. Brian DavisChief Financial Officer484.453.3300.., torii ‘ s partnership with JT includes in-licensing of high-quality pharmaceuticals in addition to torii ’ independent! August 2020, verrica participated in a Type a meeting with the FDA regarding the NDA for VP-102 the. June 30, 2020 a Complete Response Letter was received from the FDA Financial ext! As well ) Upgrade to Real-Time Afterhours Application for VP-102 on July 13,.... Resulting United States under the conditionally accepted brand name YCANTH™ growth as well shipping. In-Licensing of high-quality pharmaceuticals Pharmaceutical manufacturers ) group development continued to fuel exceptional growth as well as shipping business NDA.